Victoria Socha

DocwireNews

Chronic kidney disease (CKD) is commonly associated with renal anemia. Roxadustat is the first-in-class oral hypoxia-inducible factor prolyl hydroxylase inhibitor for the treatment of anemia. Li Zheng and colleagues in China conducted a systematic review and meta-analysis to examine the efficacy and safety of roxadustat in the treatment of anemia in patients with CKD. Results were reported online in the British Journal of Clinical Pharmacology [doi.org/10.1111/bcp.15055].The researchers searched PubMed, Cochrane Library, Embase, and clinicaltrials.gov from inception to February 2021. The search included randomized controlled trials comparing the efficacy and safety of roxadustat to the efficacy and safety of an erythropoiesis-stimulating agent (ESA) or placebo in the treatment of anemia in patients with CKD.The search revealed nine randomized controlled trials involving 2743 patients. Results of the meta-analysis demonstrated that roxadustat increased hemoglobin level by 0.91 g/dL (95% confidence interval [CI], 0.47-1.43; P&lt;.05), transferrin level by 0.50 mg/dL (95% CI, 0.34-0.65; P&lt;.05), and total iron-binding capacity by 50.64 &micro;g/dL (95% CI, 36.21-65.07; P&lt;.05). There were also decreases in hepcidin (mean difference [MD], &ndash;23.16; 95% CI, &ndash;37.12 to &ndash;9.19; P&lt;.05) and ferritin (MD, &ndash;38.35; 95% CI, &ndash;67.41 to &ndash;9.29; P&lt;.05).The incidence of adverse events was similar between roxadustat and control groups. The incidence of adverse events was significantly higher among patients in the roxadustat group compared with those in the ESA group (odds ratio, 1.33; 95% CI, 1.06-1.68; P&lt;.05).In conclusion, the authors said, &ldquo;Roxadustat can significantly improve renal anemia in CKD patients by increasing hemoglobin level and iron metabolism. However, attention must be paid to the risk of serious adverse events during treatment.&rdquo;

Connie Rhee, MD

Joel M. Topf, MD, FACP

CKD Management and Cognition

NKF Spring Clinical Meetings 2025

Bradley Marder, MD

Gout Studies: Transplant Waitlisting and Bone Erosion

Jayme Locke, MD, MPH

The Promise of Xenotransplantation

Latest News

Review and Meta-Analysis: Roxadustat for Treatment of Anemia in CKD

Anemia and Kidney Disease

Chronic kidney disease (CKD) is commonly associated with renal anemia. Roxadustat is the first-in-class oral hypoxia-inducible factor prolyl hydroxylase inhibitor for the ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe